Chronic morphologically verified gastritis, variants of course
- Авторлар: Plotnikova E.Y.1, Kutsaeva A.O.2, Sukhikh A.S.3, Baranova E.N.1, Sinkov M.A.4, Nikonorova M.A.5
-
Мекемелер:
- Kemerovo State Medical University
- I.A. Kolpinsky Clinical Consultative and Diagnostic Center
- Kemerovo State University
- Research Institute of Complex Issues of Cardiovascular Diseases
- Altai State Medical University
- Шығарылым: Том 32, № 4 (2025)
- Беттер: 32-41
- Бөлім: Gastroenterology/nutriciology
- URL: https://journals.eco-vector.com/2073-4034/article/view/687695
- DOI: https://doi.org/10.18565/pharmateca.2025.4.32-41
- ID: 687695
Дәйексөз келтіру
Аннотация
Background: Gastritis is a histological diagnosis, although its prevalence is decreasing in developed countries along with the prevalence of Helicobacter pylori infection. We identified H. pylori-positive (Hp+) and H. pylori-negative (Hp-) gastritis variants to analyze relationships that have not been adequately studied in previous studies.
Objective: Evaluation of the clinical, laboratory, and histological changes in the gastric mucosa in Hp+ and Hp- gastritis.
Materials and methods: We examined 122 patients (62 with Hp+ and 60 with Hp- gastritis) aged 20 to 65 years. In addition to conventional clinical and biochemical tests, the laboratory tests included the Gastropanel. For the diagnosis of Helicobacter pylori, 2-3 available methods were used for each patient. All study participants underwent esophagogastroduodenoscopy with morphological examination of biopsy specimens according to OLGA/OLGIM criteria. The vegetative status of the examined patients was assessed. All patients were prescribed treatment for gastritis, depending on the presence of Hp infection. Differences between the comparison parameters were considered statistically different at p≤0.05.
Results: Hp- gastritis was more often verified in the antral section, while Hp+ gastritis almost always affected both the antral section and the stomach body. Metaplasia according to OLGIM 0–I was observed only in 9 patients with Hp+ gastritis (p>0.05). In the vegetative status, vagotonia prevailed, in contrast to the control (p>0.05). All patients with Hp+ gastritis were prescribed anti-Helicobacter therapy. A number of patients chose a combination composition with the commercial name Pilobact® AM and bismuth tripotassium dicitrate for 14 days, had an eradication level of 87.4%. We conducted a pharmacochemical comparative analysis of the drugs included in Pilobact® AM with reference drugs and obtained their high comparability.
Conclusion: Significant differences in clinical and laboratory parameters in patients with Hp+ Hp- gastritis were revealed only in morphological data. One of the anti-Helicobacter treatment options can be the Pilobact® AM combination, which has proven both its high efficiency in clinical observations and pharmacochemical comparability with reference drugs.
Толық мәтін

Авторлар туралы
Ekaterina Plotnikova
Kemerovo State Medical University
Хат алмасуға жауапты Автор.
Email: eka-pl@rambler.ru
ORCID iD: 0000-0002-6150-1808
SPIN-код: 4346-5012
Scopus Author ID: 57193910407
Dr. Sci. (Med.), Professor, Department of Postgraduate Training and Nursing, Head of the Clinical Gastroenterology Course
Ресей, KemerovoA. Kutsaeva
I.A. Kolpinsky Clinical Consultative and Diagnostic Center
Email: dr.kytsaeva@vk.com
ORCID iD: 0009-0006-2396-3880
Gastroenterologist
Ресей, KemerovoA. Sukhikh
Kemerovo State University
Email: suhih_as@list.ru
ORCID iD: 0000-0001-9300-5334
Cand. Sci. (Med.), Head of the Laboratory of Physicochemical Studies of Pharmacologically Active and Natural Compounds
Ресей, KemerovoE. Baranova
Kemerovo State Medical University
Email: bevgn@rambler.ru
Cand. Sci. (Med.), Associate Professor, Department of Hospital Therapy and Clinical Pharmacology
Ресей, KemerovoM. Sinkov
Research Institute of Complex Issues of Cardiovascular Diseases
Email: fox2you@mail.ru
ORCID iD: 0000-0002-2494-8694
Cand. Sci. (Med.), Cardiovascular Surgeon
Ресей, KemerovoM. Nikonorova
Altai State Medical University
Email: ma.nikulina@mail.ru
ORCID iD: 0000-0001-6621-9310
Dr. Sci. (Med.), Associate Professor, Professor at the Department of Infectious Diseases with the Course of Continuous Professional Education
Ресей, BarnaulӘдебиет тізімі
- Toyoshima O., Nishizawa T., Sakitani K., et al. Helicobacter pylori eradication improved the Kyoto classification score on endoscopy. JGH Open. 2020;4(5):909–14. https://dx.doi.org/10.1002/jgh3.12360
- Weng C.Y., Xu J.L., Sun S.P., et al. Helicobacter pylori eradication: Exploring its impacts on the gastric mucosa. World J Gastroenterol. 2021;27(31):5152–70. https://dx.doi.org/10.3748/wjg.v27.i31.5152
- Fock K.M., Graham D.Y., Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol. 2013;10(8):495–500. https://dx.doi.org/10.1038/nrgastro.2013.96
- Rugge M., Correa P., Di Mario F., et al. OLGA staging for gastritis: A tutorial. Digestive and Liver Disease. 2008;40(8):650–8. doi: 10.1016/j.dld.2008.02.030.
- Rugge M., de Boni M., Pennelli G., et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther. 2010;31(10):1104–11. https://dx.doi.org/10.1111/j.1365-2036.2010.04277.x
- Guarner J., Mohar A., Parsonnet J., Halperin D. The association of Helicobacter pylori with gastric cancer and preneoplastic gastric lesions in Chiapas, Mexico. Cancer. 1993;71(2):297–301. https://dx.doi.org/10.1002/1097-0142(19930115)71:2<297:aid-cncr2820710205>3.0.co;2-9
- Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. https://dx.doi.org/10.3322/caac.20107
- Sugano K., Tack J., Kuipers E.J., et al.; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–67. https://dx.doi.org/10.1136/gutjnl-2015-309252
- Malfertheiner P., Megraud F., Rokkas T., et al.; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022:gutjnl-2022-327745. https://dx.doi.org/10.1136/gutjnl-2022-327745
- Sung J.J., Lin S.R., Ching J.Y., et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000;119(1):7–14. https://dx.doi.org/10.1053/gast.2000.8550
- Haber M.M., Hunt B., Freston J.W., et al. Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. Aliment Pharmacol Ther. 2010;32(1):83–96. https://dx.doi.org/10.1111/j.1365-2036.2010.04310.x
- Peura D.A., Haber M.M., Hunt B., Atkinson S. Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients. J Clin Gastroenterol. 2010;44(3):180–5. https://dx.doi.org/10.1097/MCG.0b013e3181ac9830
- Merchant S.H., VanderJagt T., Lathrop S., Amin M.B. Sporadic duodenal bulb gastrin-cell tumors: association with Helicobacter pylori gastritis and long-term use of proton pump inhibitors. Am J Surg Pathol. 2006;30(12):1581–7. https://dx.doi.org/10.1097/01.pas.0000213326.86992.98
- Sugano K. Should we still subcategorize helicobacter pylori-associated dyspepsia as functional disease? J Neurogastroenterol Motil. 2011;17(4):366–71. https://dx.doi.org/10.5056/jnm.2011.17.4.366
- Suzuki H., Nishizawa T., Hibi T. Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia? J Gastroenterol Hepatol. 2011;26(Suppl. 3):42–5. https://dx.doi.org/10.1111/j.1440-1746.2011.06629.x
- Miwa H., Ghoshal U.C., Fock K.M., et al. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol. 2012;27(4):626–41. https://dx.doi.org/10.1111/j.1440-1746.2011.07037.x.
- Asaka M., Kato M., Takahashi S., et al.; Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15(1):1–20. https://dx.doi.org/10.1111/j.1523-5378.2009.00738.x
- Moayyedi P., Soo S., Deeks J., et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2001;(1):CD002096. https://dx.doi.org/10.1002/14651858.CD002096
- Yagi K., Nakamura A., Sekine A. Characteristic endoscopic and magnified endoscopic findings in the normal stomach without Helicobacter pylori infection. J Gastroenterol Hepatol. 2002;17(1):39–45. https://dx.doi.org/10.1046/j.1440-1746.2002.02665.x
- Okubo M., Tahara T., Shibata T., et al. Usefulness of magnifying narrow-band imaging endoscopy in the Helicobacter pylori-related chronic gastritis. Digestion. 2011;83(3):161–6. https://dx.doi.org/10.1159/000321799
- Rugge M., Genta R.M. Staging and grading of chronic gastritis. Hum Pathol. 2005;36(3):228–33. https://dx.doi.org/10.1016/j.humpath.2004.12.008
- Mansour-Ghanaei F., Joukar F., Yeganeh S., et al. OLGA- and OLGIM-Based Staging in the Patients with Gastritis and Endoscopy Indications. Turk J Gastroenterol. 2022;33(2):95–102. https://dx.doi.org/10.5152/tjg.2021.201154
- Yagi K., Nakamura A., Sekine A. Comparison between magnifying endoscopy and histological, culture and urease test findings from the gastric mucosa of the corpus. Endoscopy. 2002;34(5):376–81. https://dx.doi.org/10.1055/s-2002-25281
- Nagasaki N., Ito M., Boda T., et al. Identification of Helicobacter pylori-related gastric cancer risk using serological gastritis markers and endoscopic findings: a large-scale retrospective cohort study. BMC Gastroenterol. 2022;22(1):299. https://dx.doi.org/10.1186/s12876-022-02381-z
- Kageyama T. Pepsinogens, progastricsins, and prochymosins: structure, function, evolution, and development. Cell Mol Life Sci. 2002;59(2):288–306. https://dx.doi.org/10.1007/s00018-002-8423-9
- Juan Cai W., Yin L., Kang Q., et al. The Serum Pepsinogen Test as a Predictor of Kazakh Gastric Cancer. Sci Rep. 2017;7:43536. https://dx.doi.org/10.1038/srep43536
- Zhang J., Guo J.Z., Xiao H.L., et al. Simultaneous detection of different serum pepsinogens and its primary application. World J Gastroenterol. 2010;16(24):3072–7. https://dx.doi.org/10.3748/wjg.v16.i24.3072
- Di Mario F., Crafa P., Barchi A., et al. Pepsinogen II in gastritis and Helicobacter pylori infection. Helicobacter. 2022;27(2):e12872. https://dx.doi.org/10.1111/hel.12872
- Lespessailles E., Toumi H. Proton Pump Inhibitors and Bone Health: An Update Narrative Review. Int J Mol Sci. 2022;23(18):10733. https://dx.doi.org/10.3390/ijms231810733
- Castellana C., Pecere S., Furnari M., et al. Side effects of long-term use of proton pump inhibitors: practical considerations. Pol Arch Intern Med. 2021;131(6):541–9. https://dx.doi.org/10.20452/pamw.15997
- Chinzon D., Domingues G., Tosetto N., Perrotti M. Safety of Long-term Proton Pump Ingibitors: Facts and Myths. Arq Gastroenterol. 2022;59(2):219–25. https://dx.doi.org/10.1590/S0004-2803.202202000-40
- Kotelevets S.M., Chekh S.A., Chukov S.Z. Effectiveness of serological markers of gastric mucosal atrophy in the gastric precancer screening and in cancer prevention. World J Gastrointest Endosc. 2024;16(8):462–71. https://dx.doi.org/10.4253/wjge.v16.i8.462
- Wang R., Chen X.Z. Prevalence of atrophic gastritis in southwest China and predictive strength of serum gastrin-17: A cross-sectional study (SIGES). Sci Rep. 2020;10(1):4523. https://dx.doi.org/10.1038/s41598-020-61472-7
- Gašenko E., Bogdanova I., Sjomina O., et al. Assessing the utility of pepsinogens and gastrin-17 in gastric cancer detection. Eur J Cancer Prev. 2023;32(5):478–84. https://dx.doi.org/10.1097/CEJ.0000000000000791
- Li Y., Zhao Y., Li Y., et al. Gastrin-17 induces gastric cancer cell epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway. J Physiol Biochem. 2021;77(1):93–104. https://dx.doi.org/10.1007/s13105-020-00780-y
- Zeng J., Shen Y., Xu S., Yang R. Analysis of gastrin-17 and its related influencing factors in physical examination results. Immun Inflamm Dis. 2023;11(10):e993. https://dx.doi.org/10.1002/iid3.993
- Qin Y., Geng J.X., Huang B. Clinical value of serum pepsinogen in the diagnosis and treatment of gastric diseases. World J Gastrointest Oncol. 2023;15(7):1174–81. https://dx.doi.org/10.4251/wjgo.v15.i7.1174
- Capelle L.G., de Vries A.C., Haringsma J., et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71(7):1150–8. https://dx.doi.org/10.1016/j.gie.2009.12.029
- Ben Slama S., Ben Ghachem D., Dhaoui A., et al. Gastrites chroniques à hélicobacter pylori: évaluation des systèmes OLGA et OLGIM [Helicobacter pylori gastritis: assessment of OLGA and OLGIM staging systems]. Pan Afr Med J. 2016;23:28. French. https://dx.doi.org/10.11604/pamj.2016.23.28.8839
- Плотникова Е.Ю. и др. Программа для ЭВМ «Корвег». Свидетельство об официальной регистрации № 200061883 от 8 сентября 2000 г. Российского Агентства по патентам и товарным знакам. [Plotnikova E.Yu. et al. Computer program «Korveg». Certificate of official registration No. 200061883 dated September 8, 2000 of the Russian Agency for Patents and Trademarks. (In Russ.)].
- Клинические рекомендации. Гастрит и дуоденит. URL: https://cr.minzdrav.gov.ru/view-cr/708_2 [Clinical recommendations. Gastritis and duodenitis. (In Russ.)]. URL: https://cr.minzdrav.gov.ru/view-cr/708_2
- Sonnenberg A., Genta R.M. Changes in the Gastric Mucosa With Aging. Clin Gastroenterol Hepatol. 2015;13(13):2276–81. https://dx.doi.org/10.1016/j.cgh.2015.02.020
- Sipponen P., Maaroos H.I. Chronic gastritis. Scand J Gastroenterol. 2015;50(6):657–67. https://dx.doi.org/10.3109/00365521.2015.1019918
- Agréus L., Hellström P.M., Talley N..J., et al. Towards a healthy stomach? Helicobacter pylori prevalence has dramatically decreased over 23 years in adults in a Swedish community. United European Gastroenterol J. 2016;4(5):686–96. https://dx.doi.org/10.1177/2050640615623369
- Muszyński J., Ziółkowski B., Kotarski P., et al. Gastritis – facts and doubts. Prz Gastroenterol. 2016;11(4):286–95. https://dx.doi.org/10.5114/pg.2016.57793
- Cutler A.F., Prasad V.M., Santogade P. Four-year trends in Helicobacter pylori IgG serology following successful eradication. Am J Med. 1998;105(1):18–20. https://dx.doi.org/10.1016/s0002-9343(98)00134-x
- Nordenstedt H., Graham D.Y., Kramer J.R., et al. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol. 2013;108(1):65–71. https://dx.doi.org/10.1038/ajg.2012.372
- Zavros Y., Rieder G., Ferguson A., et al. Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. Gastroenterology. 2002;122(1):119–33. https://dx.doi.org/10.1053/gast.2002.30298
- Минушкин О.Н., Зверков И.В., Володин Д.В. и др. Эффективность препарата «Пилобакт АМ» в эрадикационной терапии язвенной болезни двенадцатиперстной кишки. Врач. 2008;(5):67–9. [Minushkin O.N., Zverkov I.V., Volodin D.V., et al. Efficiency of the drug «Pilobact AM» in eradication therapy of duodenal ulcer. Vrach. 2008;(5):67–9. (In Russ.)].
- Кантуринова А.З., Тулина М.К., Жетписова Л.Б. Пилобакт Нео в лечении язвенной болезни. Медицинский журнал Западного Казахстана. 2011;4(32):67–9. [Kanturinova A.Z., Tulina M.K., Zhetpisova L.B. Pilobact Neo in the treatment of peptic ulcer disease. Medical Journal of Western Kazakhstan. 2011;4(32):67–9. (In Russ.)].
- Зангиева Е.В., Ивашев М.Н. Эффективность Пилобакта. Международный журнал экспериментального образования. 2017;1:115–6. [Zangieva E.V., Ivashev M.N. Efficiency of Pilobact. International Journal of Experimental Education. 2017;1:115–6. (In Russ.)].
- Старостин Б.Д. Модифицированная Пилобакт АМ-основанная терапия. Русский медицинский журнал. 2019;5:8–12. [Starostin B.D. Modified Pilobact AM-based therapy. Russkiy meditsinskiy zhurnal. 2019;5:8–12. (In Russ.)].
- Пахомова И.Г. Современные возможности повышения эффективности эрадикационной терапии на клиническом примере. Медицинский совет. 2022;(15):28–34. [Pakhomova I.G. Modern possibilities of increasing the effectiveness of eradication therapy using a clinical example. Meditsinskiy sovet. 2022;(15):28–34. (In Russ.)]. https://dx.doi.org/10.21518/2079-701X-2022-16-15-28-34
- Барановский А.Ю., Бордин Д.С., Эмбутниекс (Таранченко) Ю.В. и др. Европейский регистр Helicobacter pylori (Hp-EuReg): анализ данных 2360 больных, получавших терапию первой линии в России. Терапевтический архив. 2018;90(2):35–41. [Baranovsky A.Yu., Bordin D.S., Embutnieks (Taranchenko) Yu.V. et al. European Helicobacter pylori Registry (Hp-EuReg): analysis of data from 2360 patients receiving first-line therapy in Russia. Terapevticheskii arkhiv. 2018;90(2):35–41. (In Russ.)]. https://dx.doi.org/10.26442/terarkh20189023542
Қосымша файлдар
